Session 1:
Tumor heterogeneity and breast cancer therapy

  1. A potential strategy to prevent drug resistance: Chromosome instability can be prevented with no changes in the induction of cell death after Chk1 depletion
  2. Analysis of Akt molecular, subcellular and tumoral code as an explanatory and predictive tool for the effectiveness of therapies against breast cancer
  3. CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A
  4. DNA polymerase iota prevents unleashed DNA elongation to promote cell survival and genomic stability
  5. Exploring the role of hyaluronan and CD44 in resistance to ErbB-2-targeted therapies in breast cancer
  7. Effect of 2’-nitroflavone on the expression of receptors associated with EGFR activity in breast cancer cells
  8. GEF-H1 drives tumor formation, motility, invasion and metastasis in breast cancer
  9. Generation of a CRISPR/Cas9 EO771-tumor platform to study breast cancer cell – immune system interactions
  10. Inhibition of SETD7 methyl-transferase activity impairs mammary epithelial cell differentiation and lactogenesis
  11. LIVER X RECEPTOR (LXR) activation may affect breast cancer risk through induction of tristetraprolin (TTP) in mamary epithelial cells
  12. Morphological and histological studies in mammary glands of GH-overexpressing transgenic mice.
  13. Parameters associated with metastatic dissemination are differentially modulated by specific isotypes of the retinoic acid receptor (RARs) in triple negative mammary cancer models
  14. Perforator flaps in the reconstruction of Breast and thorax burnts
  15. Phenotypic and functional characterization of memory Natural Killer (NKm) cells in patients with Breast Cancer (BC)
  16. Study of Foxp3 expression in tumor microenvironment and peripheral blood of breast cancer patients
  17. Tristetraprolin (TTP) down-regulation in mammary epithelial cells induces developmental delay and DUSP-6 phosphatase overexpression

Session 2: From hormone receptors to the immune system: the evolution of therapeutic targets in breast cancer

  1. Aberrant Ret expression impacts on normal mammary gland post-lactation transition enhancing cancer potential
  2. Analysis of RUNX-CBFβ as a relevant regulator of RSPO3 expression in breast cancer cells
  3. AR and ErbB-2 Interaction in Triple Negative Breast Cancer
  4. Association between higher KI67 and higher proportion of effector T CD8 lymphocytes in HER2+ Breast Cancer patients
  5. Dual galectin-8 and ALCAM silencing delays triple negative breast cancer progression
  6. Epigenetic changes induced by pesticide exposure reactivate LINE-1 retrotransposon in breast cancer and mammary epithelial cells
  7. Epigenetic modifications associated to breast cancer in metabolic syndrome-like disease mice models
  8. Epigenetics, bioelectricity and laterality of breast cancer
  9. Establishment of two Breast Cancer Patient Derived Xenograft (PDX) lines and their respective treatment-resistant PDX variant
  10. Investigating the role of CBFB in breast cancer
  11. Methods to monitor the relevance of M phase in the synthetic lethal potency of Polo-like Kinase 1 inhibitors
  12. Molecular cross-talk between ER and ID4 in breast cancer
  13. Norcantharidine treatment inhibits in vitro parameters associated with tumor progression in triple negative breast cancer cell lines
  14. Peripheral blood NK bright cells are augmented in breast cancer patients non-reaching pathologic complete response to antibody anti HER2+-based therapy
  15. RNA-seq Identifies Nuclear ErbB-2-Induced Transcriptome as a Key Driver for Triple Negative Breast Cancer Growth
  16. RUNX2 overexpression generates endocrine resistance in human luminal breast cancer xenografts
  17. Tristetraprolin (TTP) Expression is Required for Mammary Progenitor Cell Survival
  18. Working together for the family: HER oncogenes co-amplification in breast cancer

Session 3: Cancer stem cells and de-differentiated phenotype

  1. ACE2 downregulation as a resistance mechanism to VEGFR-tyrosine kinase inhibitor (VEGFR-TKI) treatment in breast cancer therapy
  2. Cytokinesis inhibition induces synthetic lethality and mitotic abnormalities in BRCA2-deficient cell lines
  3. Differentiation of 3T3-L1 preadipocytes into beige adipocytes regulate mammary tumor cells behavior
  4. Effect of Lapatinib and All-Trans Retinoic Acid (ATRA) combined treatment on mammary cancer stem cells derived from HER2 negative cell lines
  5. Emerging role of AhR / c-Src signaling in breast cancer cell migration induced by tumor acidosis
  6. Establishing histopathological criteria for breast cancer research
  7. Glycerol-3P-Acyltransferase 2 expression in MDA-MB-231 cells modulates the expression of Long Non-Coding RNAs linked to survival prediction in breast cancer patients
  8. Identification of circulating miRNAs associated to Kaiso and triple negative breast cancer in mice model
  9. In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes
  10. Influence of Structural Variants of the TRIC-CCT complex´s genes on patient survival and the main molecular pathways related to breast cancer
  11. Integrative single-cell transcriptomic analysis unveils alternative polyadenylation modulation in the mouse mammary gland
  12. Low-grade inflammation is related to KLK3 levels in breast cancer
  13. Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis
  14. Role of Thyroid Hormones in breast cancer resistance to chemotherapy
  15. Soluble tumor necrosis factor alpha fosters tumor growth, innate immune evasion and resistance to lapatinib in HER2-positive breast cancer
  16. The Kinin B1 Receptor induces the expression and secretion of IL-10 and M-CSF from breast cancer cells, favoring the differentiation and migration of macrophages
  17. Soluble factors from the tumor-adipocyte interplay stimulate morphological and metabolic changes in 3T3-L1 adipocytes

Session 4: Mouse models for studying breast cancer initiation and progression

  1. Chlorpyrifos subthreshold exposure induces epithelial-mesenchymal transition in breast cancer cells
  2. CIN-independent cell death in S phase induced by pol eta depletion
  3. Combination therapy of paclitaxel with calcitriol analogues: a new therapeutic option for Triple Negative Breast Cancer
  4. Effect of olaparib in combination with doxorubicin on MDA-MB-231 breast cancer cell line
  5. Effect of Roscovitine and mifepristone on luminal breast cancer cell proliferation
  6. Environmental exposure and mammary tumors: the pesticides action on LM3 murine breast cancer cells
  7. Evaluation of mycotherapeutic antitumoral potential of the Pleurotus ostreatus I-Fraction in breast cancer
  8. Exposure to endocrine disruptors induces proangiogenic factors in MDA-MB-231 human breast cancer cells
  9. Implications of TGF-β in the early progression of breast cancer
  10. Investigating the tumour suppressor function of RUNX1 in breast cancer
  11. Low Oct4 expression in mesenchymal stem cells contributes to the development of the bone marrow pre-metastatic niche in advanced breast cancer patients
  12. Isolation and Characterization of Extracellular Vesicles coming from Breast Cancer Cells and Macrophages
  13. Protein aggregation and hormone-related cancers: a novel approach to improve diagnosis and overcome endocrine therapy resistance?
  14. Regulation of RUNX1 by androgen receptor, a new potencial mechanism of TNBC progression
  15. RUNX1 participation on TNBC
  16. Targeting androgen receptor and WNT pathway in endocrine-resistant mammary carcinomas with high AR and low ER and PR levels
  17. Unveiling the mechanism of regulation of excessive fork elongation by Polymerase Iota